These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 29395991)
1. Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats. Zandi M; Dehghan A; Zandipoor N; Amini P; Doulati S J Craniomaxillofac Surg; 2018 Mar; 46(3):466-472. PubMed ID: 29395991 [TBL] [Abstract][Full Text] [Related]
2. Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats. Zandi M; Dehghan A; Mohammadi-Mofrad A; Amini P; Vahdatinia F J Craniomaxillofac Surg; 2017 Feb; 45(2):275-280. PubMed ID: 28087282 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw. Zandi M; Dehghan A; Amini P; Doulati S; Rezaeian L Clin Oral Investig; 2019 Nov; 23(11):3987-3993. PubMed ID: 30715621 [TBL] [Abstract][Full Text] [Related]
4. Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model. Liu J; Mattheos N; Deng C; Su C; Wang Z; Luo N; Tang H J Periodontol; 2021 Jan; 92(1):149-158. PubMed ID: 32281098 [TBL] [Abstract][Full Text] [Related]
5. Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study. Keskinruzgar A; Bozdag Z; Aras MH; Demir T; Yolcu U; Cetiner S J Oral Maxillofac Surg; 2016 Jan; 74(1):68-78. PubMed ID: 26215490 [TBL] [Abstract][Full Text] [Related]
6. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient. Neuprez A; Rompen E; Crielaard JM; Reginster JY Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929 [TBL] [Abstract][Full Text] [Related]
7. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Ohbayashi Y; Iwasaki A; Nakai F; Mashiba T; Miyake M Osteoporos Int; 2020 Mar; 31(3):577-585. PubMed ID: 31768589 [TBL] [Abstract][Full Text] [Related]
8. Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: A case-control study. Kim KM; Kim S; Hwang H; Kim HY; Kim D; Park JH; Choo H; Kim JW Oral Dis; 2024 Jul; 30(5):3286-3295. PubMed ID: 37927178 [TBL] [Abstract][Full Text] [Related]
9. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. Cheung A; Seeman E N Engl J Med; 2010 Dec; 363(25):2473-4. PubMed ID: 20950167 [No Abstract] [Full Text] [Related]
10. Teriparatide therapy for osteonecrosis of the jaw. Chtioui H; Lamine F; Daghfous R N Engl J Med; 2011 Mar; 364(11):1081-2; author reply 1082. PubMed ID: 21410382 [No Abstract] [Full Text] [Related]
11. Treatment of Osteonecrosis of the Jaw. Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825 [TBL] [Abstract][Full Text] [Related]
12. Teriparatide for bone loss in the jaw. Grey A N Engl J Med; 2010 Dec; 363(25):2458-9. PubMed ID: 20950165 [No Abstract] [Full Text] [Related]
13. Systemic application of teriparatide for steroid induced osteonecrosis in a rat model. Dong Y; Li Y; Huang C; Gao K; Weng X BMC Musculoskelet Disord; 2015 Jul; 16():163. PubMed ID: 26163144 [TBL] [Abstract][Full Text] [Related]
14. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw. Tsai KY; Huang CS; Huang GM; Yu CT J Rheumatol; 2010 Mar; 37(3):675; author reply 676. PubMed ID: 20197569 [No Abstract] [Full Text] [Related]
15. Further development of the MRONJ minipig large animal model. Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745 [TBL] [Abstract][Full Text] [Related]
16. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699 [TBL] [Abstract][Full Text] [Related]
17. Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw: A randomized, controlled, prospective experimental study in rats. Zandi M; Dehghan A; Ghadermazi K; Malekzadeh H; Akbarzadeh M J Craniomaxillofac Surg; 2015 Nov; 43(9):1823-8. PubMed ID: 26355024 [TBL] [Abstract][Full Text] [Related]
18. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice. Yu W; Su J Oral Dis; 2020 Apr; 26(3):609-620. PubMed ID: 31903673 [TBL] [Abstract][Full Text] [Related]
19. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw. Chopra K; Malhan N Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ: A Randomized Trial on Rats. Gürses G; Sur E; Cengiz ZO; Körez MK J Oral Pathol Med; 2024 Sep; 53(8):530-537. PubMed ID: 39113433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]